Moomoo AI 已提取核心信息
On January 19, 2024, BioVie Inc., a Nevada-based biopharmaceutical company, was named as a defendant in a shareholder class action lawsuit filed in the U.S. District Court for the District of Nevada. The lawsuit, titled Eric Olmstead v. BioVie Inc. et al., No. 3:24-cv-00035, alleges that BioVie made material misrepresentations and omissions concerning its business operations, compliance, and prospects, specifically regarding the study and trial of its drug NE3107. The class action represents investors who purchased BioVie securities between August 5, 2021, and November 29, 2023, and seeks unspecified monetary damages and legal costs. BioVie has stated that it believes the lawsuit is without merit and intends to defend against the claims vigorously. The company has also indicated that it cannot predict the outcome of the litigation at this stage and does not plan to file further reports on any additional similar lawsuits.
On January 19, 2024, BioVie Inc., a Nevada-based biopharmaceutical company, was named as a defendant in a shareholder class action lawsuit filed in the U.S. District Court for the District of Nevada. The lawsuit, titled Eric Olmstead v. BioVie Inc. et al., No. 3:24-cv-00035, alleges that BioVie made material misrepresentations and omissions concerning its business operations, compliance, and prospects, specifically regarding the study and trial of its drug NE3107. The class action represents investors who purchased BioVie securities between August 5, 2021, and November 29, 2023, and seeks unspecified monetary damages and legal costs. BioVie has stated that it believes the lawsuit is without merit and intends to defend against the claims vigorously. The company has also indicated that it cannot predict the outcome of the litigation at this stage and does not plan to file further reports on any additional similar lawsuits.
2024年1月19日，总部位于内华达州的生物制药公司BioVie Inc. 被指定为向美国内华达特区地方法院提起的股东集体诉讼的被告。该诉讼名为埃里克·奥尔姆斯特德诉BioVie Inc.等人，编号 3:24-cv-00035，指控BioVie就其业务运营、合规性和前景，特别是其药物 NE3107 的研究和试验做出了重大虚假陈述和遗漏。该集体诉讼涉及在2021年8月5日至2023年11月29日期间购买BioVie证券的投资者，他们寻求未指明的金钱赔偿和法律费用。BioVie表示，它认为该诉讼没有法律依据，并打算对这些指控进行有力辩护。该公司还表示，现阶段无法预测诉讼结果，也不打算就任何其他类似诉讼提交进一步的报告。
2024年1月19日，总部位于内华达州的生物制药公司BioVie Inc. 被指定为向美国内华达特区地方法院提起的股东集体诉讼的被告。该诉讼名为埃里克·奥尔姆斯特德诉BioVie Inc.等人，编号 3:24-cv-00035，指控BioVie就其业务运营、合规性和前景，特别是其药物 NE3107 的研究和试验做出了重大虚假陈述和遗漏。该集体诉讼涉及在2021年8月5日至2023年11月29日期间购买BioVie证券的投资者，他们寻求未指明的金钱赔偿和法律费用。BioVie表示，它认为该诉讼没有法律依据，并打算对这些指控进行有力辩护。该公司还表示，现阶段无法预测诉讼结果，也不打算就任何其他类似诉讼提交进一步的报告。
有用
没用